Working Paper Article Version 3 This version is not peer-reviewed

Complementary Application of the Ozonized Saline Solution in Mild and Severe Patients with Pneumonia Covid-19: A Non-randomized Pilot Study

Version 1 : Received: 16 June 2020 / Approved: 18 June 2020 / Online: 18 June 2020 (13:13:39 CEST)
Version 2 : Received: 30 June 2020 / Approved: 3 July 2020 / Online: 3 July 2020 (08:46:48 CEST)
Version 3 : Received: 10 July 2020 / Approved: 12 July 2020 / Online: 12 July 2020 (16:30:51 CEST)

How to cite: Schwartz, A.; Martínez-Sánchez, G.; Menassa de Lucía, A.; Mejía Viana, S.; Alina Mita, C. Complementary Application of the Ozonized Saline Solution in Mild and Severe Patients with Pneumonia Covid-19: A Non-randomized Pilot Study. Preprints 2020, 2020060233 Schwartz, A.; Martínez-Sánchez, G.; Menassa de Lucía, A.; Mejía Viana, S.; Alina Mita, C. Complementary Application of the Ozonized Saline Solution in Mild and Severe Patients with Pneumonia Covid-19: A Non-randomized Pilot Study. Preprints 2020, 2020060233

Abstract

Currently, there is no effective antiviral therapy recommended for the new coronavirus disease 2019 pneumonia (COVID-19). The purpose of this pilot study was to evaluate the safety of Ozonized Saline Solution (O3SS) used as a complementary therapy in adult patients COVID-19. Twenty-five adult patients who were hospitalized with mild to severe COVID-19 symptoms, who met the inclusion criteria and were being treated from April 18rd to April 26th, 2020, at the Viamed Virgen De La Paloma Hospital, Madrid, Spain were included in this study. Patients were allocated to receive standard care (SC) that included 200-400 mg hydroxychloroquine twice daily for 5-7 days plus Tocilizumab 400 mg twice daily for 5 days, low molecular weight heparin (LMWH) and 40 mg-60 mg metil-prednisone plus O3SS, 200 mL, 3-5 µg/mL daily for 10 days. No control group was included, data were compared to clinical trials in this subject. Primary outcomes of treatment with O3SS were an improvement of clinical symptoms and a reduction in mortality. Secondary end points evaluated included participant clinical status, laboratory examinations, and duration of viral shedding. None of the patients treated with SC + O3SS died. Improvements in symptoms such as dyspnea, weakness, and reduction in body temperature were observed and corresponded with an improvement of laboratory finding including D-dimer, fibrinogen, LDH, and CRP. No side effects from the O3SS treatment were observed. Conclusions: COVID-19 patients with mild to severe symptoms who received intravenous O3SS as a complementary therapy demonstrated no side effects. This preliminary data will be served as base for a future study of the efficacy of this therapy.

Subject Areas

ozone therapy; ozonized saline solution; SARS-CoV-2; COVID-19; pneumonia

Comments (1)

Comment 1
Received: 12 July 2020
Commenter: Gregorio Sanchez
Commenter's Conflict of Interests: Author
Comment: add in title: a non-randomized pilot study
Minor grammatical corrections
Adding in Material and Methods, data of the ethic committee approval
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.